Self-report of current and prior antiretroviral drug use in comparison to the medical record among HIV-infected patients receiving primary HIV care
- PMID: 21294218
- PMCID: PMC3118653
- DOI: 10.1002/pds.2096
Self-report of current and prior antiretroviral drug use in comparison to the medical record among HIV-infected patients receiving primary HIV care
Abstract
Objective: Patient antiretroviral (ARV) therapy knowledge is essential for regimen adherence, successful therapeutic response, and minimization of resistance evolution. Moreover, a complete and accurate patient ARV history is needed to construct efficacious and tolerable future regimens. In this study we assessed the ability of HIV-infected patients receiving care in a university infectious diseases clinic to accurately recall current and past ARVs.
Methods: A convenience sample (n = 205) of UNC HIV Clinical Cohort participants (n = 1840) completed a comprehensive in-person interview. Patients were asked about current and ever ARV use and were provided proprietary and generic ARV names and photographs. Self-reported sensitivity for current and ever ARV use (proportion that correctly identified all recorded ARVs), was calculated using the medical record as the gold standard.
Results: One hundred and eighty-five patients had received ARVs at some point after enrollment in the cohort study (ever users). For current ARV use (n = 138), self-reported sensitivity was 63% (95% CI: 54-71). For ever use (n = 185), sensitivity was 18% (95% CI: 13-24).
Conclusion: Self-reported cumulative ARV use is not accurate. Since HIV-infected patients are prescribed a number of medications over their treatment course, it is necessary to develop new medication reconciliation techniques that are not dependent on patient memory or knowledge in order to improve patient outcomes.
Copyright © 2011 John Wiley & Sons, Ltd.
Conflict of interest statement
CONFLICT OF INTEREST
ESB was supported by an unrestricted fellowship from the UNC-GlaxoSmithKline Center of Excellence in Pharmacoepidemiology and Public Health at the University of North Carolina, Gillings School of Global Public Health while conducting this research. GlaxoSmithKline markets or has marketed antiretroviral medications. JJE has been a paid consultant to Merck, Pfizer, GlaxoSmithKline, Tibotec and Bristol MyersSquibb. In addition, he has received honoraria from Gilead. Each of these companies market or have marketed antiretroviral medications. None of these companies have provided support for this research. All other authors, no known conflicts.
Figures

Similar articles
-
Illness Perceptions, Medication Beliefs, and Adherence to Antiretrovirals and Medications for Comorbidities in Adults With HIV Infection and Hypertension or Chronic Kidney Disease.J Acquir Immune Defic Syndr. 2016 Dec 1;73(4):403-410. doi: 10.1097/QAI.0000000000001075. J Acquir Immune Defic Syndr. 2016. PMID: 27171742 Free PMC article.
-
The impact of taking or not taking ARVs on HIV stigma as reported by persons living with HIV infection in five African countries.AIDS Care. 2009 Nov;21(11):1357-62. doi: 10.1080/09540120902862576. AIDS Care. 2009. PMID: 20024711 Free PMC article.
-
Adherence in the treatment of patients with extensively drug-resistant tuberculosis and HIV in South Africa: a prospective cohort study.J Acquir Immune Defic Syndr. 2014 Sep 1;67(1):22-9. doi: 10.1097/QAI.0000000000000221. J Acquir Immune Defic Syndr. 2014. PMID: 24872138 Free PMC article.
-
HIV-1 antiretroviral resistance: scientific principles and clinical applications.Drugs. 2012 Jun 18;72(9):e1-25. doi: 10.2165/11633630-000000000-00000. Drugs. 2012. PMID: 22686620 Free PMC article. Review.
-
Antiretroviral (ARV) drug resistance in the developing world.Evid Rep Technol Assess (Full Rep). 2007 Sep;(156):1-74. Evid Rep Technol Assess (Full Rep). 2007. PMID: 18088163 Free PMC article. Review.
Cited by
-
Correlates of antiretroviral utilization among hospitalized HIV-infected crack cocaine users.AIDS Res Hum Retroviruses. 2012 Sep;28(9):1007-14. doi: 10.1089/AID.2011.0329. Epub 2012 Mar 2. AIDS Res Hum Retroviruses. 2012. PMID: 22214200 Free PMC article.
-
The state of disparities in opportunistic infection prophylaxis for blacks with HIV/AIDS.Med Care. 2012 Nov;50(11):920-7. doi: 10.1097/MLR.0b013e31826c85d1. Med Care. 2012. PMID: 23047780 Free PMC article. Review.
-
Efficacy, adherence and tolerability of once daily tenofovir DF-containing antiretroviral therapy in former injecting drug users with HIV-1 receiving opiate treatment: results of a 48-week open-label study.Eur J Med Res. 2011 Oct 10;16(10):427-36. doi: 10.1186/2047-783x-16-10-427. Eur J Med Res. 2011. PMID: 22024421 Free PMC article.
-
Higher Clinician-Patient Communication Is Associated With Greater Satisfaction With HIV Care.J Int Assoc Provid AIDS Care. 2021 Jan-Dec;20:23259582211054935. doi: 10.1177/23259582211054935. J Int Assoc Provid AIDS Care. 2021. PMID: 34787014 Free PMC article.
-
Efficacy of a nucleoside-sparing regimen of darunavir/ritonavir plus raltegravir in treatment-naive HIV-1-infected patients (ACTG A5262).AIDS. 2011 Nov 13;25(17):2113-22. doi: 10.1097/QAD.0b013e32834bbaa9. AIDS. 2011. PMID: 21857490 Free PMC article. Clinical Trial.
References
-
- Braitstein P, Brinkhof MW, Dabis F, et al. Mortality of HIV-1-infected patients in the first year of antiretroviral therapy: comparison between low-income and high-income countries. Lancet. 2006;367(9513):817–824. - PubMed
-
- Clotet B, Bellos N, Molina JM, et al. Efficacy and safety of darunavir–ritonavir at week 48 in treatment-experienced patients with HIV-1 infection in POWER 1 and 2: a pooled subgroup analysis of data from two randomised trials. Lancet. 2007;369(9568):1169–1178. - PubMed
-
- Madruga JV, Cahn P, Grinsztejn B, et al. Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-1: 24-week results from a randomised, double-blind, placebo-controlled trial. Lancet. 2007;370(9581):29–38. - PubMed
-
- Moore RD, Keruly JC, Gebo KA, et al. An improvement in virologic response to highly active antiretroviral therapy in clinical practice from 1996 through 2002. J Acquir Immune Defic Syndr. 2005;39(2):195–198. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous